Delivery Order SPE2DP20D0002-SPE2DP25F2789

Award Date 1/28/25
Potential Completion Date 2/4/25
Potential Value $5.3M
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $158,804.73, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a large, foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 vaccines to support military immunization programs. This is a firm-fixed-price delivery order contract with an ultimate completion date of August 27, 2024. Teva Pharmaceuticals USA, Inc. has a long history of supplying...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $158,804.73 fixed-price delivery order is for the supply of Adenovirus Type 4 vaccine, which supports military immunization programs. Teva Pharmaceuticals USA, Inc. holds multiple Indefinite Delivery Contracts (IDCs) with federal agencies, including a $64,352,514.80 IDC with the Department of Veterans...
This federal contract award, valued at $990,941.58, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is a delivery order for the supply of Adenovirus Type 4 vaccine, a critical medical product that supports military immunization programs. The contract is a firm-fixed-price arrangement with a period of performance through March 25, 2025. Teva Pharmaceuticals USA, Inc....
This federal contract award, valued at $317,609.46, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc. for the delivery of the Adenovirus Type 4 vaccine. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit pharmaceutical manufacturer that serves as a major supplier of critical drug products to various U.S. federal government agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of...
This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical was made to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $1,111,633.11 firm-fixed-price delivery order is for the supply of Adenovirus Type 4 vaccine, a critical product used in military immunization programs. This award falls under a larger $5.7 million Indefinite Delivery Contract (IDC) that establishes Teva as the national prime vendor to provide...
The U.S. Defense Logistics Agency (DLA) awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $317,609.46 Delivery Order contract for the supply of Adenovirus Type 4 vaccines. This order falls under DLA Troop Support Medical's larger portfolio of contracts supporting military immunization programs. The contract has a firm fixed-price, with a completion date of June 25, 2024. Teva Pharmaceuticals USA, Inc. is a major supplier of critical drugs and...
This federal contract award, valued at $1,588,047.30, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 A vaccine, a critical product for military immunization programs. The delivery order contract is firm-fixed-price with a period of performance through April 30, 2024. While the original solicitation is not provided, this award is...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the delivery of Adenovirus Type 4 vaccine. The firm-fixed-price delivery order has a ceiling value of $476,414.19 and a completion date of April 30, 2024. The contract is not set aside for a specific business designation. Teva Pharmaceuticals USA, Inc. is a leading global pharmaceutical company that...
This federal contract award, with a ceiling value of $1,270,437.84, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a large, foreign-owned, for-profit pharmaceutical manufacturer. The contract is a delivery order for the provision of Adenovirus Type 4 vaccines, which support military immunization programs. This delivery order is part of a larger Indefinite Delivery Contract (IDC) vehicle held by Teva with the DLA, valued at $5,687,207.30,...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 vaccine, which supports military immunization programs. The firm-fixed-price delivery order has a ceiling value of $660,627.72 and a period of performance through March 25, 2025. This award is not set-aside and represents one of Teva's many unrestricted contract awards...
  • SPE2DP20D0002
    Indefinite Delivery Contract
  • SPE2DP20D0002-SPE2DP25F2789
    Delivery Order

This federal contract award, valued at $5,285,021.76, was issued by the Defense Logistics Agency (DLA) to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is a firm-fixed-price delivery order for the supply of Adenovirus Type 4 vaccine, which supports military immunization programs. The award has an ultimate completion date of February 4, 2025. Teva Pharmaceuticals USA, Inc. is a major supplier of critical pharmaceutical products to various federal agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons, and Indian Health Service. The company holds two significant Indefinite Delivery Contracts (IDCs) with federal agencies, one with the VA National Acquisition Center for glatiramer acetate injections and another with the DLA for Levalbuterol HCL Solution, demonstrating its critical role in maintaining pharmaceutical supplies for federal healthcare programs. This award is an unrestricted contract, meaning Teva competed as a large business without any set-aside designations.

Generated 4/29/25, 9:44 AM